Onglyza May Increase Death Rate
Onglyza Increased Risk of All-Cause Mortality. A review published by the U.S. Food and Drug Administration (FDA) on April 10, 2015 indicates that Astra Zeneca’s key diabetes drugs—Onglyza (saxagliptin)—may be tied to "a significantly increased risk of all-cause mortality." Onglyza is a key AstraZeneca diabetes product that, in … [Read more...] about Onglyza May Increase Death Rate
Serious Side Effects Associated with DPP-4 Inhibitor Type 2 Diabetes Drugs
Diabetes Drugs Serious Side Effects. Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors), a class of oral diabetes medications that includes Januvia, Onglyza, Trajenta, and Nesina, treat Type 2 diabetes by blocking DPP-4. Oral DPP-4 inhibitors work by increasing incretin levels in the pancreas which, in turn, inhibits the … [Read more...] about Serious Side Effects Associated with DPP-4 Inhibitor Type 2 Diabetes Drugs
Invokana Increases Risk of Bone Fractures, FDA Warns
The Food and Drug Administration (FDA) issued a safety announcement in September warning patients and health care providers of an increased risk of bone fractures in patients taking the type 2 diabetes drugs Invokana and Invokamet (canagliflozin). The FDA deemed the new safety announcement necessary because bone fractures have … [Read more...] about Invokana Increases Risk of Bone Fractures, FDA Warns
FDA Warns Newer Type 2 Diabetes Drugs May Cause Ketoacidosis
The Food and Drug Administration (FDA) is warning that some of the newer Type 2 diabetes medicines—canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance)—may cause ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones. Patients with ketoacidosis may require … [Read more...] about FDA Warns Newer Type 2 Diabetes Drugs May Cause Ketoacidosis
Byetta, Victoza Raise More Cancer Fears
Byetta Increased The Risk Of Pancreatic Cancer. A new study is adding to concerns that type 2 drugs like Byetta and Victoza could increase the likelihood that a patient will develop pancreatitis and pancreatic cancer. The study found that Byetta increases the risk for pancreatitis - a known risk factor for pancreatic cancer … [Read more...] about Byetta, Victoza Raise More Cancer Fears
Avandia Curbs
Avandia Curbs Will be in Effect. The U.S. Food & Drug Administration (FDA) has finally announced how and when it will implement new restrictions for Avandia and other diabetes drugs containing rosiglitazone. Because of the new restrictions, Avandia will no longer be available at retail pharmacies after November … [Read more...] about Avandia Curbs
Byetta Linked to Increased Fatality Rates
Byetta Implicated In Deaths. Byetta has been implicated in six deaths, four more than federal regulators reported last week. The additional deaths were revealed late yesterday during a conference call conducted by Amylin Pharmaceuticals Inc. and Eli Lilly & Co, the co-marketers of the diabetes drugs. The companies … [Read more...] about Byetta Linked to Increased Fatality Rates
Warnings Added to Diabetes Drugs
GlaxoSmithKline and Eli Lilly & Company Diabetes Drugs May Cause Liver Damage. GlaxoSmithKline and Eli Lilly & Company have added warnings about heart and liver risks to the labels of their diabetes drugs, which are similar to a medication that was withdrawn from the market in 2000 because of links to fatal liver damage. The Food … [Read more...] about Warnings Added to Diabetes Drugs
Diabetes Drugs Heart Failure Risk
Diabetes Drugs May Cause Heart Failure. Diabetics who use oral drugs to control their disease face a 50 percent increase in the risk for heart failure compared to those who do not take use the drugs, researchers said Tuesday at a American College of Cardiology conference. The drugs belong to a class of drugs called glitazones and … [Read more...] about Diabetes Drugs Heart Failure Risk
